<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491230</url>
  </required_header>
  <id_info>
    <org_study_id>0443-11-TLV</org_study_id>
    <nct_id>NCT01491230</nct_id>
  </id_info>
  <brief_title>Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>NETs post HSCT</acronym>
  <official_title>Neutrophil Extracellular Traps (NETs) Formation Post-hematopoietic Stem Cell Transplantation (HSCT) and Its Relation to Chemotaxis and Creation of Reactive Oxygen Species</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Max Planck Institute for Infection Biology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meir Hospital, Kfar Saba, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identifying the post-transplantation phase wherein neutrophils recover their ability to&#xD;
      release NETs could shed new light on the mechanism responsible for the increased&#xD;
      susceptibility to infection among these patients and aid in improving their prophylactic&#xD;
      antimicrobial treatment. Therefore, we aim to examine neutrophil extracellular traps (NETs)&#xD;
      formation, in relation to other neutrophil functions like chemotaxis, superoxide production,&#xD;
      hydrogen peroxide production, and the presence of myeloperoxidase, in pediatric patients&#xD;
      undergoing autologous and allogeneic hematopoietic stem cell transplantation (HSCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although neutrophil engraftment takes place 10 to 14 days after autologous HSCT, and 15 to 30&#xD;
      days after allogeneic HSCT, using an ablative conditioning regimen, neutrophil dysfunction&#xD;
      may persist for longer periods. Relatively scant data exists on neutrophil function following&#xD;
      HSCT. After autologous HSCT, the respiratory burst and phagocytosis may be decreased for up&#xD;
      to 3 months. After allogeneic HSCT, respiratory burst and chemotaxis are generally decreased&#xD;
      for 4 to 6 months. Factors such as continuation of chemotherapy, immunosuppression, and GVHD&#xD;
      contribute to this prolonged dysfunction. No data exist on reconstitution of NETs following&#xD;
      HSCT.&#xD;
&#xD;
      Nets production and other neutrophil functions will be examined at several time points:&#xD;
      before transplantation, at neutrophil engraftment, 6 weeks, 3 months, 6 months, 9 months, 1&#xD;
      year, 1.5 years, 2 years, and 3 years post-transplant, or until normalization of neutrophil&#xD;
      function at 2 consecutive time points. Data gathered on patients will cover:&#xD;
&#xD;
        1. Demographics.&#xD;
&#xD;
        2. Tumor histological type, staging, previous chemotherapy regimen, and initial response to&#xD;
           treatment.&#xD;
&#xD;
        3. HSCT procedure - type of conditioning regimen, type of graft (autologous or allogeneic -&#xD;
           related donor/unrelated donor/cord blood), use of bone marrow stem cells (SCs) or&#xD;
           peripheral mobilized SCs, number of SCs given, post-transplant immunosuppression,&#xD;
           post-transplant prophylactic antimicrobial treatment, infections during the study&#xD;
           period, and GVHD occurrence and treatment.&#xD;
&#xD;
      Neutrophil examinations will be done in collaboration with the Laboratory for Leukocyte&#xD;
      Function of the Department of Pediatrics, Meir Medical Center, Kfar Saba and NETs&#xD;
      visualization with the Department of Cellular Microbiology at the Max Planck Institute for&#xD;
      Infection Biology, Berlin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Childhood Cancer</condition>
  <arm_group>
    <arm_group_label>25 autologous/25 allogeneic patients</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10cc of peripheral venous blood will be collected from each patient at several time points:&#xD;
      Before transplant, at neutrophil engraftment, 6 weeks, 3 months, 4 months, 6 months, 9&#xD;
      months, 1 year, 1.5 years, 2 years, and 3 years post-transplant, or until normalization of&#xD;
      NETs formation in 2 consecutive examinations.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Infants, children and adolescents undergoing autologous and allogeneic HSCT at the&#xD;
        pediatric hemato-oncology departement of Dana children's Hospital, Tel-Aviv Sourasky&#xD;
        Medical Center, Tel-Aviv, Israel.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All infants, children and adolescents undergoing autologous and allogeneic HSCT at the&#xD;
             pediatric hemato-oncology departement of Dana children's Hospital.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe background diseases (like diabetes and lupus) that there is no data in the&#xD;
             literature on their influence on NETs production.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sivan Achituv, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel-Aviv Sourasky Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sivan Achituv, MD</last_name>
    <phone>972-3-6974270</phone>
    <email>sivanbrg@netvision.net.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronit Elhasid, MD</last_name>
    <phone>972-3-6974252</phone>
    <email>ronite@tasmc.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dana Children's Hospital, Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivan Achituv, MD</last_name>
      <phone>972-3-6974270</phone>
      <email>sivanbrg@netvision.net.il</email>
    </contact>
    <investigator>
      <last_name>Sivan Achituv, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 11, 2011</study_first_submitted>
  <study_first_submitted_qc>December 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>Michal Roll PhD,MBA</investigator_full_name>
    <investigator_title>Director, Division of Research and Developement</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>neutrophil extracellular traps</keyword>
  <keyword>autologous hematopoietic stem cell transplantation</keyword>
  <keyword>allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>chemotaxis</keyword>
  <keyword>superoxide production</keyword>
  <keyword>hydrogen peroxide production</keyword>
  <keyword>myeloperoxidase</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

